Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized trial of intensified pharmacological treatment versus treatment as usual after first antidepressant treatment failure in major depressive disorder
2023-506617-21-00Phase 3Authorised
- Sponsor
- University Medical Center Utrecht
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 3, randomised trial of esketamine, ketamine, amitriptyline, clomipramine, escitalopram and 21 more in major depressive disorder (MDD) (2 arms), sponsored by University Medical Center Utrecht. Primary endpoint: Change in MADRS total score at 6 weeks. Planned start Aug 2024; status: authorised.
02
Drugs
esketamineketamineamitriptylineclomipramineescitalopram
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2023-506617-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506617-21-00.